Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Qualité des Produits Animaux (QuaPA); Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE); Institut Pascal (IP); Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne); Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA); Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne); Université Clermont Auvergne (UCA); Direction de la Recherche Clinique et de l’Innovation CHU Clermont-Ferrand (DRCI); CHU Clermont-Ferrand; Sorbonne Université (SU); Lille Neurosciences & Cognition - U 1172 (LilNCog); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Pôle Psychiatrie et Neurologie Grenoble; Centre Hospitalier Universitaire CHU Grenoble (CHUGA); Université Grenoble Alpes (UGA); Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 (ISC-MJ); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS); Université de Lyon; Hôpital neurologique et neurochirurgical Pierre Wertheimer CHU - HCL; Hospices Civils de Lyon (HCL); NS-Park/FCRIN Network; UMS 015; Institut du Cerveau = Paris Brain Institute (ICM); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS); Département de Neuroradiologie CHRU Montpellier; Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Hôpital Gui de Chauliac CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Université de Montpellier (UM); Institut d’Imagerie Fonctionnelle Humaine CHU Montpellier (I2FH); Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); CHU Montpellier = Montpellier University Hospital; EuroMov - Digital Health in Motion (Euromov DHM); IMT - MINES ALES (IMT - MINES ALES); Institut Mines-Télécom Paris (IMT)-Institut Mines-Télécom Paris (IMT)-Université de Montpellier (UM); Institut des Maladies Neurodégénératives Bordeaux (IMN); Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS); Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux); University of Otago Dunedin, Nouvelle-Zélande; New Zealand Brain Research Institute (NZBRI); Hôpital Maison Blanche; Hôpital universitaire Robert Debré Reims (CHU Reims); Centre de Recherche en Sciences et Technologies de l'Information et de la Communication - EA 3804 (CRESTIC); Université de Reims Champagne-Ardenne (URCA); CHU Henri Mondor Créteil; IMRB - "NeuroPsychologie Interventionnelle" Créteil (U955 Inserm - UPEC); Institut Mondor de Recherche Biomédicale (IMRB); Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402); Université de Poitiers = University of Poitiers (UP)-Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie )-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM); CHU Limoges; Centre d'investigation clinique de Toulouse (CIC 1436); Université Toulouse III - Paul Sabatier (UT3); Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Toulouse NeuroImaging Center (ToNIC); Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI); Université Toulouse - Jean Jaurès (UT2J); Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3); Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J); Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3); Université de Toulouse (UT); The IPD-study was funded by the French Ministry of Health (grant PHRC2016), the French Parkinson’s Disease Foundation, the Federation for Brain Research, the NS-PARK Network and sponsored by the University Hospital of Clermont Ferrand, France.
    • بيانات النشر:
      CCSD
      Elsevier
    • الموضوع:
      2022
    • Collection:
      Université de Poitiers: Publications de nos chercheurs.ses (HAL)
    • نبذة مختصرة :
      International audience ; Several postmortem studies have shown iron accumulation in the substantia nigra of Parkinson's disease patients. Iron concentration can be estimated via MRI-R2∗ mapping. To assess the changes in R2∗ occurring in Parkinson's disease patients compared to controls, a multicentre transversal study was carried out on a large cohort of Parkinson's disease patients (n = 163) with matched controls (n = 82). In this study, 44 patients and 11 controls were removed due to motion artefacts, 21 patient and 6 controls to preserve matching. Thus, 98 patients and 65 age and sex-matched healthy subjects were selected with enough image quality. The study was conducted on patients with early to late stage Parkinson's disease. The images were acquired at 3Tesla in 12 clinical centres. R2∗ values were measured in subcortical regions of interest (substantia nigra, red nucleus, striatum, globus pallidus externus and globus pallidus internus) contralateral (dominant side) and ipsilateral (non dominant side) to the most clinically affected hemibody. As the observed inter-subject R2∗ variability was significantly higher than the disease effect, an original strategy (intrasubject subcortical quantitative referencing, ISQR) was developed using the measurement of R2∗ in the red nucleus as an intra-subject reference. R2∗ values significantly increased in Parkinson's disease patients when compared with controls; in the substantia nigra (SN) in the dominant side (D) and in the non dominant side (ND), respectively (PSN_D and PSN_ND < 0.0001). After stratification into four subgroups according to the disease duration, no significant R2∗ difference was found in all regions of interest when comparing Parkinson's disease subgroups. By applying our ISQR strategy, R2(ISQR)∗ values significantly increased in the substantia nigra (PSN_D and PSN_ND < 0.0001) when comparing all Parkinson's disease patients to controls. R2(ISQR)∗ values in the substantia nigra significantly increased with the disease duration (PSN_D = 0.01; ...
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/36279753; PUBMED: 36279753; PUBMEDCENTRAL: PMC9668635; WOS: 000880443300005
    • الرقم المعرف:
      10.1016/j.nicl.2022.103231
    • الدخول الالكتروني :
      https://hal.inrae.fr/hal-03857470
      https://hal.inrae.fr/hal-03857470v1/document
      https://hal.inrae.fr/hal-03857470v1/file/Khedher_2022.pdf
      https://doi.org/10.1016/j.nicl.2022.103231
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.822F24BA